Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
57,950.29 +1,530.36 (+2.71%) CMC Crypto 200
1,203.59 -5.10 (-0.42%)
AGC Inc. (5201.T)
| Previous close | 5,285.00 |
| Open | 5,310.00 |
| Bid | 5,222.00 x 0 |
| Ask | 5,229.00 x 0 |
| Day's range | 5,219.00 - 5,310.00 |
| 52-week range | 4,721.00 - 5,928.00 |
| Volume | |
| Avg. volume | 943,180 |
| Market cap | 1.121T |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 49.51 |
| EPS (TTM) | 105.50 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | 210.00 (4.02%) |
| Ex-dividend date | 27 Dec 2024 |
| 1y target est | 5,831.00 |
Business WireThe AGC Group Obtains Its First Cradle to Cradle Certified® for Mirox MNGE Interior Glass Products in Asia
TOKYO, May 13, 2024--AGC Glass Asia’s Mirox MNGE, a low lead mirror, is awarded with Cradle to Cradle Certified® at the Bronze level based on version 3.1.
Business WireThe AGC Group Makes Donations to Help Victims of Eastern Taiwan Earthquake
TOKYO, April 19, 2024--The AGC Group had announced that it will donate 3 million yen to help those affected by the eastern Taiwan Earthquake.
- MediaOutReach
AGC Biologics Announces Plans for New Manufacturing Site in Yokohama Japan
The new four-story 20,000 m² facility will feature mammalian cell culture, messenger RNA and cell therapy services and be operational in 2026SEATTLE, USA - News Direct - 04 January 2024 - AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan. The new site is a part of the CDMO’s strategic growth strategy to create more high-quali
